Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,-Reference-Cited by-同舟云学术

Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,

Published:2023-01 Issue:1 Volume:47 Page:102053
ISSN:2210-7401
Container-title:Clinics and Research in Hepatology and Gastroenterology
language:en
Short-container-title:Clinics and Research in Hepatology and Gastroenterology

Author:

Zou Cai-yan,Sun Yan,Liang Jun

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference74 articles.

1. Visvikis-Siest S: nutrigenetic interactions might modulate the antioxidant and anti-inflammatory status in mastiha-supplemented patients with NAFLD;Kanoni;Front Immunol,2021

2. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement;Eslam;J. Hepatol.,2020

3. Molecular and pathophysiological links between metabolic disorders and inflammatory bowel diseases;Hyun;Int J Mol Sci,2021

4. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of population-based observational studies;Jarvis;PLoS Med,2020

5. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis;Leoni;World J. Gastroenterol.,2018

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of the efficacy and safety of hypoglycemic treatments in patients with non-alcoholic fatty liver disease and type-2 diabetes: a systematic review and Bayesian network analysis;European Journal of Clinical Pharmacology;2023-09-08

2. Pharmacokinetic, toxicological, and clinical considerations for the treatment of type 2 diabetes in patients with liver disease: a comprehensive update;Expert Opinion on Drug Metabolism & Toxicology;2023-08-03

3. Comparative effects between old and new antidiabetic agents on metabolic- associated fatty liver disease (MAFLD);Diabetes Epidemiology and Management;2023-07

4. Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease;International Journal of Molecular Sciences;2023-05-26

5. Type 2 diabetes mellitus, non-alcoholic fatty liver disease and cardiovascular disease: causal relationships and the role of anti-diabetic drugs;FOCUS. Endocrinology;2023-05-10